Acadia Pharma (ACAD) Misses Q4 EPS by 1c; Offers FY23 Revenue Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $27.58 -1.57%
EPS Growth %: -52.4%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -52.4%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.26), $0.01 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $136.5 million versus the consensus estimate of $134.23 million.
GUIDANCE:
Acadia Pharma sees FY2023 Nuplazid sales of $520-530 million, versus the consensus of $569 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- ABM Industries (ABM) Reports In-Line Q3 EPS; raises guidance
- BMO Capital Starts Carter's (CRI) at Outperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
